198 related articles for article (PubMed ID: 22952939)
1. Activity of trifluoperazine against replicating, non-replicating and drug resistant M. tuberculosis.
Advani MJ; Siddiqui I; Sharma P; Reddy H
PLoS One; 2012; 7(8):e44245. PubMed ID: 22952939
[TBL] [Abstract][Full Text] [Related]
2. Antitubercular activity of trifluoperazine, a calmodulin antagonist.
Ratnakar P; Murthy PS
FEMS Microbiol Lett; 1992 Oct; 76(1-2):73-6. PubMed ID: 1427006
[TBL] [Abstract][Full Text] [Related]
3. Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant Mycobacterium tuberculosis.
Gadre DV; Talwar V; Gupta HC; Murthy PS
Int Clin Psychopharmacol; 1998 May; 13(3):129-31. PubMed ID: 9690980
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
5. Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages.
Khan A; Sarkar S; Sarkar D
Int J Antimicrob Agents; 2008 Jul; 32(1):40-5. PubMed ID: 18538548
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide.
Villar R; Vicente E; Solano B; Pérez-Silanes S; Aldana I; Maddry JA; Lenaerts AJ; Franzblau SG; Cho SH; Monge A; Goldman RC
J Antimicrob Chemother; 2008 Sep; 62(3):547-54. PubMed ID: 18502817
[TBL] [Abstract][Full Text] [Related]
7. Anti-Mycobacterial Activity of Tamoxifen Against Drug-Resistant and Intra-Macrophage Mycobacterium tuberculosis.
Jang WS; Kim S; Podder B; Jyoti MA; Nam KW; Lee BE; Song HY
J Microbiol Biotechnol; 2015 Jun; 25(6):946-50. PubMed ID: 25639719
[TBL] [Abstract][Full Text] [Related]
8. A Novel Small-Molecule Inhibitor of the
Sukheja P; Kumar P; Mittal N; Li SG; Singleton E; Russo R; Perryman AL; Shrestha R; Awasthi D; Husain S; Soteropoulos P; Brukh R; Connell N; Freundlich JS; Alland D
mBio; 2017 Feb; 8(1):. PubMed ID: 28196957
[TBL] [Abstract][Full Text] [Related]
9. High-throughput screening of compounds library to identify novel inhibitors against latent Mycobacterium tuberculosis using streptomycin-dependent Mycobacterium tuberculosis 18b strain as a model.
Sharma S; Bhat R; Singh R; Sharma S; Wazir P; Singh PP; Vishwakarma RA; Khan IA
Tuberculosis (Edinb); 2020 Sep; 124():101958. PubMed ID: 32791471
[TBL] [Abstract][Full Text] [Related]
10. Neuroleptic drugs in the treatment of tuberculosis: Minimal inhibitory concentrations of different phenothiazines against Mycobacterium tuberculosis.
Vesenbeckh S; Krieger D; Bettermann G; Schönfeld N; Bauer TT; Rüssmann H; Mauch H
Tuberculosis (Edinb); 2016 May; 98():27-9. PubMed ID: 27156615
[TBL] [Abstract][Full Text] [Related]
11. A class of hydrazones are active against non-replicating Mycobacterium tuberculosis.
Bonnett SA; Dennison D; Files M; Bajpai A; Parish T
PLoS One; 2018; 13(10):e0198059. PubMed ID: 30332412
[TBL] [Abstract][Full Text] [Related]
12. Targeting human macrophages for enhanced killing of intracellular XDR-TB and MDR-TB.
Martins M; Viveiros M; Couto I; Amaral L
Int J Tuberc Lung Dis; 2009 May; 13(5):569-73. PubMed ID: 19383188
[TBL] [Abstract][Full Text] [Related]
13. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB).
Martins M; Viveiros M; Ramos J; Couto I; Molnar J; Boeree M; Amaral L
Int J Antimicrob Agents; 2009 May; 33(5):479-82. PubMed ID: 19155160
[TBL] [Abstract][Full Text] [Related]
14. In vitro potency of 2-(((2-hydroxyphenyl)amino)methylene)-5,5-dimethylcyclohexane-1,3-dione against drug-resistant and non-replicating persisters of Mycobacterium tuberculosis.
Rather MA; Bhat ZS; Lone AM; Maqbool M; Bhat BA; Ahmad Z
J Glob Antimicrob Resist; 2021 Jun; 25():202-208. PubMed ID: 33789204
[TBL] [Abstract][Full Text] [Related]
15. Multimetallic Microparticles Increase the Potency of Rifampicin against Intracellular Mycobacterium tuberculosis.
Ellis T; Chiappi M; García-Trenco A; Al-Ejji M; Sarkar S; Georgiou TK; Shaffer MSP; Tetley TD; Schwander S; Ryan MP; Porter AE
ACS Nano; 2018 Jun; 12(6):5228-5240. PubMed ID: 29767993
[TBL] [Abstract][Full Text] [Related]
16. Delamanid Kills Dormant Mycobacteria
Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
[TBL] [Abstract][Full Text] [Related]
17. Activity of human beta defensin-1 and its motif against active and dormant Mycobacterium tuberculosis.
Sharma R; Saikia UN; Sharma S; Verma I
Appl Microbiol Biotechnol; 2017 Oct; 101(19):7239-7248. PubMed ID: 28856417
[TBL] [Abstract][Full Text] [Related]
18. In vitro combinatory activity of piperine and anti-tuberculosis drugs in Mycobacterium tuberculosis.
Hegeto LA; Caleffi-Ferracioli KR; Nakamura-Vasconcelos SS; Almeida AL; Baldin VP; Nakamura CV; Siqueira VLD; Scodro RBL; Cardoso RF
Tuberculosis (Edinb); 2018 Jul; 111():35-40. PubMed ID: 30029912
[TBL] [Abstract][Full Text] [Related]
19. New 1-hydroxy-2-thiopyridine derivatives active against both replicating and dormant Mycobacterium tuberculosis.
Salina EG; Ryabova O; Vocat A; Nikonenko B; Cole ST; Makarov V
J Infect Chemother; 2017 Nov; 23(11):794-797. PubMed ID: 28527650
[TBL] [Abstract][Full Text] [Related]
20. Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy.
Tanner L; Mashabela GT; Omollo CC; de Wet TJ; Parkinson CJ; Warner DF; Haynes RK; Wiesner L
Microbiol Spectr; 2021 Oct; 9(2):e0043421. PubMed ID: 34585951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
